Maes K, De Smedt E, Kassambara A, Hose D, Seckinger A, Van Valckenborgh E, Menu E, Klein B, Vanderkerken K, Moreaux J, De Bruyne E. In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma. Oncotarget. 2015. Download the PDF
Summary of the Study
Histone deacetylase inhibitors (HDACi) and DNA methyltransferase inhibitors (DNMTi) are emerging epigenetic therapies in multiple myeloma (MM). This study investigates the in vivo transcriptional response to quisinostat (HDACi) and decitabine (DNMTi) using the 5T33MM murine MM model.
Key findings
Quisinostat and decitabine deregulated 504 and 154 genes, respectively
62 quisinostat- and 25 decitabine-regulated genes were predictive of patient survival
These were used to create a DNA methylation and histone acetylation score
- High scores correlated with immature, proliferative MM phenotypes and poor overall survival
Gene enrichment analysis revealed links to immune activation, lymphocyte function, and T-helper-1 development
Findings support the rationale for combining HDACi with immunomodulatory agents (IMiDs)
In this study, Alboukadel Kassambara contributed to the gene expression data analysis, identifying transcriptional changes induced by epigenetic treatments and linking them to patient survival and immune-modulatory pathways.
Citation
Publication: In Oncotarget
Date: February 1, 2015
Type: Journal Article
PDF: Download the PDF
Scientific Contributions
Here are more scientific abstracts authored or co-authored by Alboukadel Kassambara. These contributions span computational biology, bioinformatics, biostatistics, machine learning, and multi-omics, with a focus on immuno-oncology and translational research.
